EpiBiologics presented new data demonstrating the unique capabilities of its EpiTAC platform at the 16th Annual PEGS Europe conference (November 5-7, 2024 in Barcelona, Spain) and the 2024 Antibody Engineering and will be presenting again at Therapeutics US conference (December 15-18, 2024 in San Diego, California).  

EpiTAC bispecific antibodies leverage cell-surface degrader receptors enriched in disease tissue to selectively degrade membrane and extracellular targets with activity superior to antibody or small molecule blockade. New data being presented demonstrate EpiTACs’ ability to remove target proteins specifically in disease tissue, sparing healthy tissue and increasing efficacy.  

“We’re pleased to present in vivo data demonstrating significant platform validation and the potential for meaningful therapeutic benefit of EpiTACs not only in oncology, where our initial focus has been, but also in high-need immune disorders,” said Shyra Gardai, Chief  Scientific Officer of EpiBiologics.  

Presentation highlights  

By selecting degrader receptors enriched in disease tissue, EpiBiologics reports that its EGFR-targeting bispecific EpiTAC antibody drives synergistic anti-tumour activity in vivo while preserving EGFR signalling in normal tissue.

EGFR EpiTAC also achieves mutation-agnostic degradation of EGFR in multiple tumour models, enabling a meaningful therapeutic approach for broad patient populations in non-small cell lung cancer (NSCLC) and other EGFR-driven cancers.

EpiTACs exhibit potential in autoimmunity by localising degradation to T regulatory cells and driving cell-selective activity. This provides a powerful approach to overcoming limitations of immune therapies that simultaneously affect both pro- and anti-inflammatory immune cells, limiting their effectiveness. 

The EpiTAC platform can degrade disease-causing GPCRs by a number of different strategies. Targeted degradation of GPCRs is a key achievement given their importance in a number of diseases, including pain and autoimmune/inflammatory and neurological diseases. 

“EpiBiologics has achieved major milestones this year, including advancing a tissue-selective EGFR programme toward the clinic, localising degradation to specific immune cell subsets for autoimmunity, and degrading GPCRs, a difficult-to-drug target class,” said Ann Lee-Karlon, President and CEO of EpiBiologics. “We are excited to expand the breadth of our platform to address a wide range of diseases while making important progress on our pipeline of EpiTAC bispecific antibody therapies.”